Bridging Early Discovery to Market Readiness: What Are the Proven Pathways for Drug Development?

Drug formulation defines the dosage form and process needed to achieve target exposure with controlled variability, stability and scalable manufacturing.

The right, phase-appropriate design can secure exposure, protect study endpoints and set a molecule on a scalable path to market.

In this Xtalks Spotlight, featuring Dave Miller, PhD, Chief Scientific Officer at AustinPx, we explore how a phase-appropriate, data-driven formulation strategy de-risks development from first experiments to launch.

Dr. Miller described a practical, phase-appropriate roadmap that starts with deep molecular understanding, protects clinical readouts from formulation-driven variability and converges on a scalable, patient-centric commercial product.

He emphasized decisions grounded in rigorous pre-formulation and material science, comparative data from rapid screens and a living formulation strategy that evolves with clinical data.

Early Discovery to Market Readiness: Know Your Molecule’s DNA

Bridging early discovery to market readiness requires a connected, phase-appropriate strategy that anticipates downstream needs from day one. Dr. Miller defined the concept as an end-to-end plan that joins early molecular insight, pre-formulation rigor, clinical performance and late-stage scale-up into a single continuum so teams avoid costly resets.

As he put it, “When we talk about bridging early discovery to market readiness, what we’re really talking about is building a development strategy that connects every stage of the journey, from our first initial preformulation experiments all the way to commercial manufacturing.”

And although speed is often of the essence, Dr. Miller said “it’s not just about getting into the clinic quickly. It’s about setting the stage for success later on in late-stage development, in scale-up and eventually to launch.”

“We found that rigor and foresight on the front end without massive investment can prevent a lot of dead ends down the road.”

In this way, early discovery is not a silo to be handed off once an initial signal is observed, but becomes the foundation for everything that follows.

The development bridge is constructed by aligning pre-formulation rigor, material science, biopharmaceutic insight and CMC (chemistry, manufacturing and controls) foresight to the clinical and commercial objectives that will ultimately define success. The goal is not only speed, but durable continuity across phases so that pharmacokinetics, manufacturability and patient usability do not drift as a program matures.

In practice, that means starting with a thorough look at the “DNA” of the molecule and the bulk drug substance, and using those insights to guide a path that will hold up not only in the clinic but also on the manufacturing floor and in the marketplace.

Knowing your molecule’s DNA starts with rigorous characterization of both the active pharmaceutical ingredient (API) and the bulk drug substance before any formulation work begins. This involves using in silico assessments and pre-formulation studies to map solubility across media, permeability, melting point, polymorphism and stability to understand both obvious and subtle liabilities.

Those data feed a developability assessment that ties projected dose and exposure needs to practical options, determining whether a conventional approach will suffice or an enabling technology is required. With that foundation, the formulation can evolve phase-appropriately, protecting exposure and readouts early, then converging on a stable, scalable, patient-ready product for late-stage and commercial use.

Examining the genetic makeup of the molecule can assist in making accurate predictions about its developmental journey, Dr. Miller explained. Material science is also used to characterize the drug substance, the “bulk of which provides early manufacturing insights that will anticipate challenges before they appear in the lab or even worse, on the manufacturing floor.”

Dr. Miller said this allows for informed decision-making at every stage of the development life cycle.

“Every decision that we make thereafter is fully informed to nurture that compound towards a stable, scalable, bioavailable product that can succeed at every stage of development and clinic, willing to eventually graduate to the market. That’s what we mean when we talk about bridging early discovery to market readiness.”

When Formulation Strategy Is Uncertain: How to De-Risk at Crossroads

There can be great uncertainty surrounding formulation decisions, particularly for molecules that are complex or not in need of enablement.

Mitigating risk is key in formulation decisions. Dr. Miller noted that risk varies by class and by liability. Highly soluble and permeable compounds may progress quickly with simple, fit-for-purpose formulations that allow teams to learn rapidly in human studies. By contrast, poorly soluble assets, such as BCS Class II or IV molecules, pose higher risks in clinical programs, suffering from exposure failures and inter-patient variability that can obscure efficacy signals.

He warned that the stakes are high if exposure is not secured early enough, explaining, “You need to invest in formulation design early because if you can’t get exposure, you won’t get efficacy. As a result, a great molecule could be wrongfully discarded.”

He also pointed out how delivery choices can compromise trial outcomes, noting that formulation issues can show up in a clinical study as non-responders to treatment, skewing the data and reducing the statistical response.

Some teams may attempt to press ahead with simple formulations at higher doses to reach early milestones and optimize later, and while that can work, Dr. Miller stressed that it comes with risks. For example, for some molecules with solubility issues, interpatient variability and absorption can be problems, which can lead to underexposure in a portion of the patient population. Hence, delivery systems can significantly impact primary or secondary endpoints in a study.

Performing comparative data analysis and a sober appraisal of variability risks are essential to avoid avoidable non-responder subpopulations that weaken statistical power.

Dr. Miller said AustinPx has garnered a fair deal of experience through its own programs, building knowledge on how to navigate “nuanced cases when there is a molecule with some liabilities.”

He said it’s important to utilize strategies to make sure you “get into clinic quickly, but not jeopardize the integrity of your clinical study, and we help the client decide when and how to apply speed and when you should take the necessary time to ensure the best clinical outcome.”

After defining a phase-appropriate formulation path, there are still multiple technologies to explore, noted Dr. Miller, each with trade-offs in performance, stability and scalability.

AustinPx uses a full toolkit of conventional and enabling approaches and runs rapid head-to-head screens to generate comparative data, helping teams choose not only whether to enable but which specific tools and formulations best fit the molecule.

Crafting an effective formulation strategy pairs deep understanding of the molecule, clinical goals and risks with data-driven, collaborative decision-making.

Moving Quickly While Planning for Late-Stage and Commercial Success

New strategies, technologies and frameworks are enabling accelerated drug development in today’s landscape.

Moving quickly into clinical trials without sacrificing late-stage or commercial viability is key. Dr. Miller described a phase-appropriate progression that prioritizes flexibility early and convergence later.

At the early stage, the focus is on dose adjustment as human pharmacokinetic data come in: “In Phase I, for example, where you’re running single or multiple ascending dose studies, you need a formulation that allows you to adjust dosing precisely as feedback comes in.” For this, simple, adaptable approaches like powder in a bottle or suspension dosing are valuable as they provide the ability to make rapid dose adjustments as more information about how the molecule behaves in humans becomes available.

As programs enter early Phase II, particularly Phase IIA, there is some flexibility in dosing and refinement. The emphasis shifts toward patient-friendly dosage forms like capsules or tablets, which can be in take-home settings, while preserving the ability to titrate as dose-response relationships are refined.

As efficacy signals strengthen, the formulation should evolve toward a final presentation that not only delivers the right pharmacokinetic performance, but is stable, manufacturable at scale and competitive in the marketplace in terms of dosage form, large scale, patient demands and patient centricity.

For Dr. Miller, it’s about continuity rather than reinvention. The key, he said, is “to connect all of these stages from early to late with a common formulation philosophy, one that ensures continuity of performance stability and manufacturability throughout the program.”

Continuity avoids unnecessary pharmacokinetic drift and the re-validation burden of wholesale formulation resets between phases.

And this goes back to beginning with a deep understanding of the molecule’s DNA. Early insights should be used to build a phase-appropriate, fit-for-purpose formulation strategy that evolves with the clinical program, tackling immediate needs and deferring others until milestone data.

Conventional vs. Enabling Technologies: Choosing with Evidence

The decision to rely on conventional dosage forms or to adopt enabling technologies should be made with evidence rather than allegiance to any particular platform.

Dr. Miller explained that AustinPx always begins with a rigorous pre-formulation molecular characterization program that examines solubility across aqueous, organic and lipid media, evaluates permeability and characterizes physical attributes such as melting point and polymorphism, all while assessing stability under relevant conditions. These attributes define the molecule early on and in late stage.

Understanding the true nature of the molecule and the bulk drug substance serves as a critical foundation in formulation strategy.

Early data from molecular characterization feeds into a formal developability assessment that considers projected dose and exposure targets against the program’s therapeutic goals and target product profile.

If conventional dosage forms can meet exposure and variability requirements with high confidence, the simpler path is preferred. If they cannot, enabling technologies such as particle size reduction, lipid-based and self-emulsifying systems and amorphous solid dispersions (ASDs) manufactured by spray drying, melt extrusion or solvent anti-solvent routes may be explored.

“We always start with the science on the molecule at AustinPx,” Dr. Miller said. And this is done collaboratively with clients, sharing data transparently to “make decisions together that are grounded in data and evidence.”

Within ASDs, AustinPx works across multiple manufacturing modalities and also draws on its own proprietary technology, but the selection is ultimately driven by comparative data on performance, stability, scalability and control strategy fit at commercial scale.

Learnings to Inform Today’s Formulation Strategies

There are several key insights that drive a “molecule first,” molecule-based design strategy.

Dr. Miller emphasized that teams should “know the molecule” in depth, not only in terms of its biopharmaceutic profile but also in relation to its bulk drug substance, since manufacturability and stability begin with materials, not just with dosage form design.

Second, risk should be classified early with clear eyes. If exposure is precarious or variability risks are high, the program should deliberately buy down that risk sooner rather than allow it to surface in pivotal data sets where it can do the most damage.

Third, comparative data should replace conjecture wherever possible. Rapid, side-by-side screens that rank-order conventional and enabling options on performance, stability and scalability can transform difficult trade-offs into informed decisions that keep timelines intact.

Finally, the formulation strategy should be alive to the realities of each phase and should evolve without losing continuity, so that the pharmacokinetic profile that serves as the clinical foundation is preserved as the dosage form matures into a commercial product.

Developing complex products requires an integrated design mindset, according to Dr. Miller. “It’s not just about solubility enhancement and bioavailability enhancement, but molecules also have to deliver across not only performance, but stability, manufacturability and even intellectual property.”

For example, supersaturating drug delivery systems (SDDS), such as ASDs, nanoparticulate systems and lipid-based delivery which enhance the oral absorption of poorly soluble drugs by temporarily creating a concentration of the drug far exceeding its normal solubility, are inherently more complex than conventional forms because they stabilize a more reactive drug state, impose greater manufacturing demands and require tighter regulatory control.

A phase-appropriate approach is essential in both simple and complex cases: in early development, use an enabling intermediate to establish proof of concept without over-engineering, then evolve toward a patient-centric product that is scalable, stable and convenient for real-world use.

Dr. Miller said, “We bear some scars that we can help our clients avoid by giving them advice as to what to focus on and what to avoid. This history allows us to help our clients navigate a clear, phase-appropriate plan that balances performance, practicality and ultimately commercial vision.”

Speed and foresight are not opposites. Teams can move quickly into human studies and still make the right long-term bets if they start with rigorous characterization, protect the integrity of clinical readouts and plan intentionally for manufacturability and patient use.

By grounding decisions in data and integrating science, engineering, operations and patient considerations from the beginning, developers can avoid many of the dead ends that delay or derail otherwise promising therapies. This approach helps carry molecules efficiently and effectively from early discovery to true market readiness.

This article was created in collaboration with the sponsoring company and the Xtalks editorial team.